Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non...

73
Risk Stratification for SCD- 2020 Update Κωνσταντίνος Α. Γκατζούλης Αναπληρωτής Καθηγητής Καρδιολογίας Πανεπιστημίου Αθηνών Διευθυντής Ηλεκτροφυσιολογικού Εργαστηρίου Ιπποκράτειου Νοσοκομείου

Transcript of Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non...

Page 1: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Risk Stratification for SCD- 2020 Update

Κωνσταντίνος Α. Γκατζούλης

Αναπληρωτής Καθηγητής Καρδιολογίας Πανεπιστημίου Αθηνών

Διευθυντής Ηλεκτροφυσιολογικού Εργαστηρίου Ιπποκράτειου Νοσοκομείου

Page 2: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Conflict of interest

Dr. K.A. Gatzoulis received a supporting grand for

PRESERVE-EF study equipment

by Medtronic and GE

Page 3: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 4: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Τύποι ICD

Single chamber (VVI)

Dual chamber (DDD)

CRT-ICD

Page 5: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ICD Evolution

Page 6: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Cumulative risk of fatal events in secondary SCD prevention trials (AVID, CIDS, CASH)

Connoly SJ et al, EHJ 2000

Page 7: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

M.R.Gold και S.Nisam, PACE 23(ptII):1981, 2000

Page 8: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Moss A et al, For the MADIT II, NEJM, 2002

Page 9: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Bardy GH et al (SCD-HeFT) Investigators, New Engl J Med 352:225-237,

2005

Page 10: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Camm AJ, Nisam S, EHJ 2000

Page 11: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 12: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 13: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Variability over time (surgery, PTCA, drugs, natural history).

Stronger association with total mortality.

Intra and inter observer variability in LVEF estimation.

2/3 of SCD in patients with LVEF>30%.

Non invasive markers predict risk in patients with LVEF>40%.

LVEF Limitations

Page 14: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 15: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 16: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 17: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 18: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ML. 64 ετών ασθ. με ΟΕΜ προ 4ετίας, LV ανευρύσματα και εμμένουσα κοιλιακή ταχυκαρδία

Page 19: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 20: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ML. 64 M, OEM, LVaneurysm and Sust VT

Page 21: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

•Markers of abnormal substrate of structural heart disease

•Markers of abnormal repolarization

•Markers of abnormal autonomic balance

•Inducibility on Programmed Ventricular Stimulation

Page 22: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

• LVEF

• QRS duration

• LBBB

• Late Potentials on SAECG

• VPBs

• NSVT

Page 23: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

•Heart Rate Variability

•Heart Rate Turbulence

•Decelaration Capacity

•Baroreceptor Sensitivity

•Heart rate

Page 24: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

•QT duration

•QTc duration

•QT dispersion

•QTc dispersion

•QT dynamics (QT/RR)

•T wave alternans

Page 25: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

•Positive Programmed Ventricular

stimulation

Page 26: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Evolution of Holter Recorders

Harold L. Kennedy

Progress in Cardiovascular Diseases, Volume 56, Issue 2, 2013, 127 - 132

Page 27: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Survival LVEF and/or VPBs

0 1 2 3

Year after MI

0

20

40

60

80

100

Survivorship

Patient Group

EF>30%, VPB<10/h, n = 536

EF>30%, VPB>10/h, n = 113

EF<30%, VPB<10/h, n = 80

EF<30%, VPB>10/H, n = 37

Bigger JT. Am J Cardiol

1986;57:8B

Page 28: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Η θετική προγνωστική ακρίβεια για την εκδήλωση μειζόνων αρρυθμιολογικών συμβάντων κατά τη μετεμφραγματική περίοδο, βελτιώνεται σημαντικά όταν

πολλαπλοί προγνωστικοί δείκτες εμφανίζουν παθολογικά ευρήματα

Καρδιακές Παθήσεις, 2001

Page 29: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

SAECG, LVEF and CM (n: 1.925 patients)

Gomes JA, Cain ME, Buxton AE et al. Prediction of longterm outcomes by SAECG in patients with unsustained ventricular tachy-

cardia, EAD and left ventricular dysfunction. Circulation 2001,104:436

Ev

ent

Ra

te

Ev

ent

Ra

te

Page 30: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

D.Richards et al, Circul 1991, 83:756

Page 31: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

LVEF 40-49

SAD 0.8% / year

Page 32: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

438 ECGs

42.4% scar autopsy =

previous unrecognized MIECG abnormalities

fQRS, Prolonged QRS, Q, T inv

Page 33: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ICDs: MADIT II EF<35SCD

Exist in HFpEF

Page 34: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΑΠΟΤΕΛΕΣΜΑΤΑ ΜΕΛΕΤΗΣ PRESERVE-EF

Page 35: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

SURVIVAL FREE FROM MAJOR ARRHYTHMIC EVENTS PER GROUP

Page 36: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

G1, n=575

G2, n=204

G3, n=41

G1, pat at Risk = 1.5%

G2, pat at Risk= 4.4%

G3, pat at Risk= 22%

REFINING THE TARGET POPULATION

Page 37: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 38: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

SCD in Structural Heart Disease

Ischemic CMP Dilated CMPHypertrophic

CMPARVC Infiltrative CMP

Valvular HD

Congenital abn.

Page 39: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 40: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 41: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 42: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 43: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 44: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

14 y/o male patient with HOCM

K.Gatzoulis, J.Gialafos, HJC 2003

Page 45: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

•0: 4.6%

•1: 57.4%

•2: 25%

•3: 10.6%

•4: 2.4%

ΔΗΜΟΓΡΑΦΙΚΑ ΣΤΟΙΧΕΙΑ ΜΕΛΕΤΗΣ –ΠΛΗΘΟΣ «ΚΛΑΣΣΙΚΩΝ»

ΠΑΡΑΓΟΝΤΩΝ ΚΙΝΔΥΝΟΥ

Page 46: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΗΦΕ ΚΑΙ ΕΚΒΑΣΗ

p(X²)=4.05*10⁻⁷Ο ΜΟΝΑΔΙΚΟΣ ΑΣΘΕΝΗΣ ΣΤΟΝ ΟΠΟΙΟΝ ΕΠΗΛΘΕ ΤΟ

ΠΚΣ ΜΕ ΑΡΝΗΤΙΚΟ ΗΦΕ ΑΠΕΒΙΩΣΕ ΑΙΦΝΙΔΙΩΣ ΚΑΤΑ ΤΗΝ

ΒΑΔΙΣΗ ΚΑΙ ΣΤΗΝ ΝΕΚΡΟΤΟΜΗ ΑΝΕΦΕΡΘΗ ΠΑΡΟΥΣΙΑ

ΒΑΡΕΙΑΣ ΕΚΤΕΤΑΜΕΝΗΣ ΣΤΕΦΑΝΙΑΙΑΣ ΝΟΣΟΥ, ΧΩΡΙΣ

ΕΠΙΣΗΜΗ ΔΙΑΓΝΩΣΗ ΟΞΕΟΣ ΣΤΕΦΑΝΙΑΙΟΥ ΣΥΝΔΡΟ-

ΜΟΥ – ΙΣΩΣ ΝΑ ΚΙΝΗΤΟΠΟΙΗΘΗΚΕ ΚΟΙΛΙΑΚΗ

ΑΡΡΥΘΜΙΟΓΕΝΕΣΗ ΑΠΟ ΜΙΚΡΟΙΣΧΑΙΜΙΚΟ ΕΠΕΙΣΟΔΙΟ;

Η ΔΙΑΦΟΡΑ ΠΑΡΕΜΕΙΝΕ ΣΤΑΤΙΣΤΙΚΩΣ ΣΗΜΑΝΤΙΚΗ ΚΑΙ ΜΕΤΑ ΤΗΝ

ΣΤΑΔΙΟΠΟΙΗΣΗ ΚΑΤΑ EUROSCORE Ή ΚΛΑΣΣΙΚΟΥΣ ΠΑΡΑΓΟΝΤΕΣ

ΚΙΝΔΥΝΟΥ (≤1 ΕΝΑΝΤΙ ≥2)

ΕΞΑΙΡΕΣΗ ΤΟ ΜΕΣΟ EUROSCORE ΟΠΟΥ ΔΕΝ ΜΠΟΡΟΥΣΑΝ ΝΑ

ΥΠΟΛΟΓΙΣΘΟΥΝ ΔΙΑΦΟΡΕΣ ΛΟΓΩ ΤΗΣ ΑΠΟΥΣΙΑΣ ΣΥΜΒΑΜΑΤΩΝ

Page 47: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΑΠΟΤΕΛΕΣΜΑΤΑ ΜΕΛΕΤΗΣ

Page 48: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Marcus FI, Fontaine G. Pacing Clin Electrophysiol 1995, 18: 1298-314

Page 49: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

68 y/o M with NSVT, ARVC and inducible VT on

EPS

Page 50: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΑΚΘ σε ΣΚ

•TF

•D-Μετάθεση των μεγάλων

αγγείων

•Στένωση ισθμού αορτής

•ΑΣ

Page 51: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

CRT-P vs CRT-D

•Risk stratification including EP testing•Potential upgrading on replacement•Cost effectiveness•Both Companion as well as CARE HF data favor CRT-D

Page 52: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

CRT-P advantages

Lower cost

Lower complication rate

Less size / weight

Longer longevity

Combination with defibrillator lead

(future upgrade to CRT-D)

Page 53: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

PATIENTS(ischemic or dilated cardiomyopathy)

Left ventricular EF assessment

<35% ≥35%

Competing mortality

High Low

≤1 year survival

expectancy

>1 year survivalexpectancy

Nothing<3 NIRF ≥3 NIRF

NegativePVS

PositivePVS

Observe and

Follow-up

ICD

<3 NIRF ≥3 NIRF

NegativePVS

PositivePVS

Observe andFollow-up

ICD

NIRF Imaging

None ≥1

NegativePVS

PositivePVS

Observe and

Follow-up

ICD

Significant fibrosis

No Yes

NegativePVS

PositivePVS

Observe andFollow-up ICD

Gatzoulis K., Sideris A., Kanoupakis E., Sideris S...Koletis T. ANEC 2017

Page 54: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΧΡΗΣΙΜΟΤΗΤΑ ΚΑΤΑΛΥΣΗΣ ΕΚΤ ΣΕ

ΑΣΘΕΝΕΙΣ ΜΕ ΟΡΓΑΝΙΚΗ ΚΑΡΔΙΟΠΑΘΕΙΑ

•Ακατάπαυστη ΕΚΤ

•Συχνές εκφορτίσεις ΕΑΒΑ

•ΗΘ

•Υποβάθμιση ποιότητας ζωής - Πρόγνωση

•Αντιαρρυθμικά – Αποτελεσματικότητα;

Προαρρυθμία; Καρδιοτοξικότητα;

Page 55: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΕΝΤΟΠΙΣΜΟΣ ΕΣΤΙΑΣ VT

Page 56: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΒΗΜΑΤΟΔΟΤΙΚΗ ΧΑΡΤΟΓΡΑΦΗΣΗ

Page 57: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Gatzoulis KA, Andrikopoulos GK, Apostolopoulos T, Sotiropoulos

E, Zervopoulos G, et al, Europace 7:184-192, 2005

Page 58: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 59: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Factors affecting prognosis among HF pts

Age

CRD

PVS results

LVEF

Syncope- Presyncope

NIRFs presence (NSVT, LPs, HRT, TWA, ECG QRS morphology

MRI results

Etiology (DCMP vs CAD)

Page 60: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΗΛΙΚΙΑ

Page 61: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΛΕΙΤΟΥΡΓΙΚΗ ΚΛΑΣΗ ΚΑΤΑ ΝΥΗΑ

Page 62: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΝΕΦΡΙΚΗ ΛΕΙΤΟΥΡΓΙΑ

Page 63: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΥΠΟΚΕΙΜΕΝΟΣ ΡΥΘΜΟΣ

Page 64: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΠΟΛΥΠΑΡΑΓΟΝΤΙΚΗ ΑΝΑΛΥΣΗ

Page 65: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΕΠΙΒΙΩΣΗ ΑΝΑΛΟΓΑ ΜΕ ΤΟΝ ΑΡΙΘΜΟ ΠΑΡΑΓΟΝΤΩΝ

Page 66: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Severity of heart faulure and mode of death

Page 67: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 68: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν
Page 69: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΠΡΩΤΟΚΟΛΛΟ ΗΛΕΚΤΡΟΦΥΣΙΟΛΟΓΙΚΟΥ ΕΛΕΓΧΟΥ

ΧΡΗΣΗ S530% ΤΩΝ ΑΣΘΕΝΩΝ ΜΕ ΠΡΟΚΛΗΤΗ VT VT ΘΑ ΧΑΝΟΝΤΑΝ ΜΕ S4 ΠΡΩΤΟΚΟΛΛΑ

Zaman S et al Induction of ventricular tachycardia with the fourth extrastimulus and its

relationship to risk of arrhythmic events in patients with post-myocardial infarct left

ventricular dysfunction. Europace. 2012;14:1771–1777.

Page 70: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

ΠΡΟΤΕΙΝΟΜΕΝΟ ΠΡΩΤΟΚΟΛΛΟ ΠΡΩΙΜΗΣ

ΔΙΑΣΤΡΩΜΑΤΩΣΗΣ ΚΙΝΔΥΝΟΥ ΣΕ ΜΕΤΕΜΦΡΑΓΜΑΤΙΚΟΥΣ

ΑΣΘΕΝΕΙΣ

ΑΞΙΟΛΟΓΗΣΗ ΠΡΟ ΤΟΥ ΕΞΙΤΗΡΙΟΥ

ΚΛΑΣΜΑ ΕΞΩΘΗΣΗΣ ΑΡΙΣΤΕΡΑΣ ΚΟΙΛΙΑΣ

ΗΛΕΚΤΡΟΦΥΣΙΟΛΟΓΙΚΟ ΕΡΓΑΣΤΗΡΙΟ Α' ΚΑΡΔΙΟΛΟΓΙΚΗΣ ΚΛΙΝΙΚΗΣ ΠΑΝΕΠΙΣΤΗΜΙΟΥ

ΑΘΗΝΩΝ ΚΑΙ ΚΡΑΤΙΚΗΣ ΚΑΡΔΙΟΛΟΓΙΚΗΣ ΚΛΙΝΙΚΗΣ ΙΓΝΑ

>40%: ΠΑΡΑΚΟΛΟΥΘΗΣΗ ≤40%: 24ΩΡΟ HOLTER KAI

ΣΥΜΨΗΦΙΣΤΙΚΟ ΚΑΡΔΙΟΓΡΑΦΗΜΑ

ΕΝΑΣ Η ΠΕΡΙΣΣΟΤΕΡΟΙ ΑΝΩΜΑΛΟΙ ΑΝΑΙΜΑΚΤΟΙ

ΔΕΙΚΤΕΣ ΠΑΡΟΝΤΕΣ: ΗΛΕΚΤΡΟΦΥΣΙΟΛΟΓΙΚΟΣ ΕΛΕΓΧΟΣ

ΑΝ ΠΡΟΚΑΛΕΙΤΑΙ ΕΜΜΕΝΟΥΣΑ ΚΟΙΛΙΑΚΗ

ΤΑΧΥΑΡΡΥΘΜΙΑ>ΠΡΩΙΜΗ ΕΜΦΥΤΕΥΣΗ ΑΠΙΝΙΔΩΤΟΥ

ΧΩΡΙΣ ΠΑΘΟΛΟΓΙΚΑ ΕΥΡΗΜΑΤΑ:

ΠΑΡΑΚΟΛΟΥΘΗΣΗ

ΧΩΡΙΣ ΠΡΟΚΛΗΣΗ ΤΑΧΥΑΡΡΥΘΜΙΑΣ:

ΠΑΡΑΚΟΛΟΥΘΗΣΗ

Page 71: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Arrhythmic risk stratification in nonischemic dilated cardiomyopathy:

The reconsider study

Konstantinos a. GatzoulisASSOCIATE PROFESSOR OF CARDIOLOGYDIRECTOR, EP LABORATORYFIRST DEPARTMENT OF CARDIOLOGYUNIVERSITY OF ATHENS

Page 72: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

PROPOSED APPROACH – THE RECONSIDER STUDY

Ann Noninvasive Electrocardiol. 2017 Mar;22(2). doi: 10.1111/anec

Page 73: Risk Stratification for SCD- 2020 Update · Risk Stratification for SCD- 2020 Update ... Non invasive markers predict risk in patients with LVEF>40%. LVEF Limitations. ML. 64 ετν

Σήραγγα εκτροπής, Αχελώος 1960, Κ.Μπαλάφας